Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes

Diabetes Res Clin Pract. 2012 Feb;95(2):e27-8. doi: 10.1016/j.diabres.2011.08.016. Epub 2011 Sep 6.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Asia / epidemiology
  • Asian Continental Ancestry Group* / statistics & numerical data
  • Biomarkers / blood
  • Body Mass Index
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / physiopathology
  • Diabetic Nephropathies / blood
  • Diabetic Nephropathies / drug therapy*
  • Diabetic Nephropathies / physiopathology
  • Dipeptidyl-Peptidase IV Inhibitors / therapeutic use*
  • Female
  • Glycated Hemoglobin A / metabolism*
  • Humans
  • Male
  • Middle Aged
  • Pyrazines / therapeutic use*
  • Sitagliptin Phosphate
  • Treatment Outcome
  • Triazoles / therapeutic use*

Substances

  • Biomarkers
  • Dipeptidyl-Peptidase IV Inhibitors
  • Glycated Hemoglobin A
  • Pyrazines
  • Triazoles
  • Sitagliptin Phosphate